Flu Vaccine composition for the 2024 Flu Season

Each year the World Health Organization (WHO) puts forward its recommendations for the composition of influenza virus for us in the Southern Hemisphere influenza season.

The Australian Influenza Vaccine Committee (AIVC) recommended that the following viruses for the 2024 southern hemisphere season trivalent influenza vaccines:

Egg-based quadrivalent influenza vaccines:

  • an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
  • an A/Thailand/8/2022 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus;

Cell- or recombinant-based quadrivalent influenza vaccines:

  • an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
  • an A/Massachusetts/18/2022 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus;

The recommendation for the B/Yamagata lineage component of quadrivalent influenza vaccines remains unchanged from previous recommendations:

  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

This recommendation aligns with the recommendations made by the WHO (Further details here https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-southern-hemisphere-influenza-season).

The Therapeutic Goods Administration (TGA) has accepted the recommendations of the AIVC.